L
4.45
-0.31 (-6.51%)
| Previous Close | 4.76 |
| Open | 4.76 |
| Volume | 196,793 |
| Avg. Volume (3M) | 615,529 |
| Market Cap | 240,219,888 |
| Price / Book | 2.02 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 |
| Diluted EPS (TTM) | -3.31 |
| Total Debt/Equity (MRQ) | 10.67% |
| Current Ratio (MRQ) | 3.41 |
| Operating Cash Flow (TTM) | -88.00 M |
| Levered Free Cash Flow (TTM) | -50.43 M |
| Return on Assets (TTM) | -42.89% |
| Return on Equity (TTM) | -80.65% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Lexeo Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
1.5
| Analyst Consensus | 3.0 |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 1.50 |
|
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 121.45% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 20.00 (Oppenheimer, 349.44%) | Buy |
| Median | 15.00 (237.08%) | |
| Low | 9.00 (HC Wainwright & Co., 102.25%) | Buy |
| Average | 14.67 (229.66%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 4.72 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 15 Aug 2025 | 15.00 (237.08%) | Buy | 4.72 |
| HC Wainwright & Co. | 15 Aug 2025 | 9.00 (102.25%) | Buy | 4.72 |
| Oppenheimer | 31 Jul 2025 | 20.00 (349.44%) | Buy | 4.73 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 Aug 2025 | Announcement | Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights |
| 07 Jul 2025 | Announcement | Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia |
| 24 Jun 2025 | Announcement | Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |